PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29212189-0	2017	Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies.	quizartinib	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-34	
29212189-4	2017	While non-toxic to cell lines, quizartinib at 3 muM showed significant reversal effect on wild-type and mutant ABCG2 (R482T)-mediated MDR, and only a moderate reversal effect on mutant ABCG2 (R482G)-mediated MDR.	quizartinib	31-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	111-116	
29212189-4	2017	While non-toxic to cell lines, quizartinib at 3 muM showed significant reversal effect on wild-type and mutant ABCG2 (R482T)-mediated MDR, and only a moderate reversal effect on mutant ABCG2 (R482G)-mediated MDR.	quizartinib	31-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-190	
29212189-5	2017	Results also showed that quizartinib reversed MDR not by reducing the expression of ABCG2 protein, but by antagonizing the drug efflux function and increasing the intracellular accumulation of substrate anticancer drugs in ABCG2-overexpressing cells.	quizartinib	25-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-89	
29212189-5	2017	Results also showed that quizartinib reversed MDR not by reducing the expression of ABCG2 protein, but by antagonizing the drug efflux function and increasing the intracellular accumulation of substrate anticancer drugs in ABCG2-overexpressing cells.	quizartinib	25-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	223-228	
29212189-6	2017	Importantly, quizartinib at 30 mg/kg strongly enhanced the effect of topotecan (3 mg/kg) in ABCG2-overexpressing (H460/MX20) xenografts in athymic nude mice.	quizartinib	13-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-97	
29212189-7	2017	These results demonstrated that quizartinib potentiates the antineoplastic activity of wild-type and R482T mutant ABCG2 substrates.	quizartinib	32-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	114-119	
30553002-0	2019	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.	quizartinib	125-136	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	66-70	
30553002-0	2019	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.	quizartinib	125-136	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-76	
30553002-3	2019	Quizartinib was transported by human ABCB1 in vitro, and by mouse (m)Abcb1 and mAbcg2 in vivo.	quizartinib	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-85	
30553002-4	2019	Upon oral administration, the brain accumulation of quizartinib was 6-fold decreased by mAbcb1 and 2-fold by mAbcg2 (together: 12-fold).	quizartinib	52-63	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-115